Cargando…

Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions

INTRODUCTION: Human papillomavirus (HPV) induce many cancer conditions and cause cervical cancer, second in frequency of malignant disease in women. The aim was to develop biomarker panel for HPV-induced cervical precancerous diseases in patients infected with herpes simplex virus (HSV). MATERIAL AN...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazarenko, Liudmyla M, Nikitina, Olena E, Nikitin, Evgen V, Demchenko, Olga M, Kovtonyuk, Galyna V, Ganova, Larysa O, Bubnov, Rostyslav V, Shevchuk, Veronika O, Nastradina, Natalia M, Bila, Viktoria V, Spivak, Mykola Ya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901026/
https://www.ncbi.nlm.nih.gov/pubmed/24386936
http://dx.doi.org/10.1186/1878-5085-5-1
_version_ 1782300791255597056
author Lazarenko, Liudmyla M
Nikitina, Olena E
Nikitin, Evgen V
Demchenko, Olga M
Kovtonyuk, Galyna V
Ganova, Larysa O
Bubnov, Rostyslav V
Shevchuk, Veronika O
Nastradina, Natalia M
Bila, Viktoria V
Spivak, Mykola Ya
author_facet Lazarenko, Liudmyla M
Nikitina, Olena E
Nikitin, Evgen V
Demchenko, Olga M
Kovtonyuk, Galyna V
Ganova, Larysa O
Bubnov, Rostyslav V
Shevchuk, Veronika O
Nastradina, Natalia M
Bila, Viktoria V
Spivak, Mykola Ya
author_sort Lazarenko, Liudmyla M
collection PubMed
description INTRODUCTION: Human papillomavirus (HPV) induce many cancer conditions and cause cervical cancer, second in frequency of malignant disease in women. The aim was to develop biomarker panel for HPV-induced cervical precancerous diseases in patients infected with herpes simplex virus (HSV). MATERIAL AND METHODS: The study involved 71 women with cervical precancerous diseases (mean age 26 ± 5 years) revealed by colposcopic, cytomorphological, and ultrasound signs which were assessed according to the following: first group, 44 patients infected with HPV; second group, 27 HPV-negative patients; and third group, 30 healthy patients (controls). In cervical specimen, we identified HPV DNA of different oncogenic risk types by polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) kits (JSC SPC ‘DiaprofMed’) were used for detecting antibodies to HSV1 and/or HSV2 and for determining the avidity index. The production of pro-inflammatory cytokines, interferon-γ (IFN-γ), IFN-α, TNF-α, and interleukin-1β (IL-1β), and anti-inflammatory cytokines, IL-4, IL-10, and transforming growth factor-β1 (TGF-β1), were studied by ELISA. RESULTS: In HPV-induced cervix precancerous diseases, we identified low-avidity IgG antibodies to HSV serum of 20 patients; in the serum of 17 patients, we identified average-avidity antibodies, and high-avidity antibodies were found in 2 patients only. In 14 HPV-negative patients, we found low-avidity IgG antibodies to HSV; in 10 patients, medium avidity. Patients with low-avidity IgG antibodies to herpes virus showed high and medium oncogenic risk HPV types and a decrease of IFN-γ compared to patients with medium-avidity IgG antibodies. Production of IFN-γ was suppressed also in HPV-negative patients with cervical precancers, but we found low- and medium-avidity IgG antibodies to herpes virus. In patients with low-avidity antibodies, we observed increased level of IL-10. Level of IFN-α, IL-1β, IL-2, and IL-4 did not change in patients of all groups, but TGF-β1 increased. CONCLUSIONS: In HPV-positive patients, those with low-avidity IgG antibodies to HSV had immunosuppression, confirmed by increased TGF-β1 and violation of IFN-γ production. Therefore, in pro- and anti-inflammatory cytokines and IgG antibodies to HSV, their avidity is an important diagnostic biomarker of HPV-induced precancerous cervical diseases. Low-avidity IgG antibodies may be an indication for treatment with immunomodulators and antiviral drugs.
format Online
Article
Text
id pubmed-3901026
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39010262014-01-25 Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions Lazarenko, Liudmyla M Nikitina, Olena E Nikitin, Evgen V Demchenko, Olga M Kovtonyuk, Galyna V Ganova, Larysa O Bubnov, Rostyslav V Shevchuk, Veronika O Nastradina, Natalia M Bila, Viktoria V Spivak, Mykola Ya EPMA J Research INTRODUCTION: Human papillomavirus (HPV) induce many cancer conditions and cause cervical cancer, second in frequency of malignant disease in women. The aim was to develop biomarker panel for HPV-induced cervical precancerous diseases in patients infected with herpes simplex virus (HSV). MATERIAL AND METHODS: The study involved 71 women with cervical precancerous diseases (mean age 26 ± 5 years) revealed by colposcopic, cytomorphological, and ultrasound signs which were assessed according to the following: first group, 44 patients infected with HPV; second group, 27 HPV-negative patients; and third group, 30 healthy patients (controls). In cervical specimen, we identified HPV DNA of different oncogenic risk types by polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) kits (JSC SPC ‘DiaprofMed’) were used for detecting antibodies to HSV1 and/or HSV2 and for determining the avidity index. The production of pro-inflammatory cytokines, interferon-γ (IFN-γ), IFN-α, TNF-α, and interleukin-1β (IL-1β), and anti-inflammatory cytokines, IL-4, IL-10, and transforming growth factor-β1 (TGF-β1), were studied by ELISA. RESULTS: In HPV-induced cervix precancerous diseases, we identified low-avidity IgG antibodies to HSV serum of 20 patients; in the serum of 17 patients, we identified average-avidity antibodies, and high-avidity antibodies were found in 2 patients only. In 14 HPV-negative patients, we found low-avidity IgG antibodies to HSV; in 10 patients, medium avidity. Patients with low-avidity IgG antibodies to herpes virus showed high and medium oncogenic risk HPV types and a decrease of IFN-γ compared to patients with medium-avidity IgG antibodies. Production of IFN-γ was suppressed also in HPV-negative patients with cervical precancers, but we found low- and medium-avidity IgG antibodies to herpes virus. In patients with low-avidity antibodies, we observed increased level of IL-10. Level of IFN-α, IL-1β, IL-2, and IL-4 did not change in patients of all groups, but TGF-β1 increased. CONCLUSIONS: In HPV-positive patients, those with low-avidity IgG antibodies to HSV had immunosuppression, confirmed by increased TGF-β1 and violation of IFN-γ production. Therefore, in pro- and anti-inflammatory cytokines and IgG antibodies to HSV, their avidity is an important diagnostic biomarker of HPV-induced precancerous cervical diseases. Low-avidity IgG antibodies may be an indication for treatment with immunomodulators and antiviral drugs. BioMed Central 2014-01-06 /pmc/articles/PMC3901026/ /pubmed/24386936 http://dx.doi.org/10.1186/1878-5085-5-1 Text en Copyright © 2014 Lazarenko et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lazarenko, Liudmyla M
Nikitina, Olena E
Nikitin, Evgen V
Demchenko, Olga M
Kovtonyuk, Galyna V
Ganova, Larysa O
Bubnov, Rostyslav V
Shevchuk, Veronika O
Nastradina, Natalia M
Bila, Viktoria V
Spivak, Mykola Ya
Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions
title Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions
title_full Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions
title_fullStr Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions
title_full_unstemmed Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions
title_short Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions
title_sort development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901026/
https://www.ncbi.nlm.nih.gov/pubmed/24386936
http://dx.doi.org/10.1186/1878-5085-5-1
work_keys_str_mv AT lazarenkoliudmylam developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions
AT nikitinaolenae developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions
AT nikitinevgenv developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions
AT demchenkoolgam developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions
AT kovtonyukgalynav developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions
AT ganovalarysao developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions
AT bubnovrostyslavv developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions
AT shevchukveronikao developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions
AT nastradinanataliam developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions
AT bilaviktoriav developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions
AT spivakmykolaya developmentofbiomarkerpaneltopredictpreventandcreatetreatmentstailoredtothepersonswithhumanpapillomavirusinducedcervicalprecancerouslesions